February 23, 2024New England Journal of Medicine

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

View Full Paper

Ask AI

Bookmark

Authors

MWMichael E. WechslerNational Jewish Health PNParameswaran NairSt. Joseph’s Healthcare Hamilton BTBenjamin TerrierHôpital Cochin

Discussion

Member takes

Implication

Randomized noninferiority trial demonstrates noninferior remission with benralizumab versus mepolizumab in eosinophilic granulomatosis with polyangiitis, suggesting a viable therapeutic option.

Key Points

Benralizumab achieved noninferior remission compared with mepolizumab in relapsing or refractory eosinophilic granulomatosis with polyangiitis, with comparable safety over 52 weeks.
Remission occurred in 59% of benralizumab recipients and 56% of mepolizumab recipients during late-stage visits, with both cohorts demonstrating similar accrued disease control.
Multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial assigned 140 adults to subcutaneous benralizumab or mepolizumab alongside standard vasculitis care.
Supports benralizumab as an effective targeted treatment for eosinophilic granulomatosis with polyangiitis, potentially facilitating greater withdrawal of oral glucocorticoids.

Cite This Study

Wechsler et al. (2024) studied this question.

synapsesocial.com/papers/68e77c8eb6db6435876f0cfd https://doi.org/10.1056/nejmoa2311155

View Full Paper

Ask AI

Bookmark

Implication

Randomized noninferiority trial demonstrates noninferior remission with benralizumab versus mepolizumab in eosinophilic granulomatosis with polyangiitis, suggesting a viable therapeutic option.

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

Discussion

Member takes

Implication

Key Points

Cite This Study

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider